Illumina (ILMN) and Nashville Biosciences said Thursday that Alnylam Pharmaceuticals (ALNY) has joined the Alliance for Genomic Discovery.
Alnylam will use the alliance's genomic database to boost drug target discovery, the companies said.
Alnylam is the ninth member of the alliance joining AbbVie (ABBV), Amgen (AMGN), AstraZeneca (AZN), Bayer, Bristol Myers Squibb (BMY), GSK (GSK), Merck (MRK), and Novo Nordisk (NVO), the companies said.
Price: 103.16, Change: +2.29, Percent Change: +2.27
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.